January 25th, 2018
For Immediate Release
To Whom It May Concern
Mitsui & Co., Ltd.
Notice for share transfers and deconsolidation of MBK Healthcare Partners Ltd.
Mitsui & Co., Ltd. ("Mitsui", Head Office: Tokyo, President and CEO: TatsuoYasunaga) announced that , MBK Healthcare Partners Ltd. (“MBKHP”), a wholly
owned subsidiary, has transferred its entire shares in IHH Healthcare Berhad(“IHH”) to Mitsui, and that Mitsui plans to liquidate this subsidiary.
As a result of the share transfers, approximately ¥9.0 billion gains on the reversalof deferred tax liability on undistributed profits is expected to be recorded inMitsui's full year consolidated financial results for the fiscal year ending March2018. This profit is not included in the consolidated financial result revised
forecasts announced by Mitsui on November 2nd, 2017.
1. Reason for the deconsolidation
The status of MBKHP has changed from a consolidated subsidiary to an
unconsolidated subsidiary as a result of reduction in paid-in capital afterinvestments held by MBKHP have been transferred to Mitsui, and Mitsui's plan toliquidate MBKHP. MBKHP was established for the purpose of managing its
investments in IHH. The recent business environment has led to theaforementioned transfer of investments and the planned liquidation as part ofMitsui's cost-cutting and streamlining measures.
2. MBK Healthcare Partners Ltd.

Company Name

MBK Healthcare Partners Limited

Address

The United Kingdom

Representative

Takeshi Saito, Director

Established

5th April 2011

Capital1,239,000,000 SGD (Before transfer)

Business Operation

Management of investments in IHH

Shareholder

Mitsui & Co., Ltd. 100%

Relationshipwith Capital relationship: Mitsui & Co., Ltd. has a 100% stake in

Mitsui & Co., Ltd.

MBKHP.
Personnel Relationship: Mitsui & Co., Ltd. has directors in
MBKHP.
Business relationship: There is no business relationship to bestated.

3. Status of owned shares before and after capital reduction
Before1,238,685,428(Number of voting rights:1,238,685,428, Ownership:100%)After1(Number of voting rights:1, Ownership:100%)

4. Dates
Capital reduction: January 25th, 2018
Liquidation: Resolution of liquidation will be scheduled on January 29th, 2018.
Registration of liquidation will be expected by the end of September, 2018.
5. IHH Healthcare BerhadCompany nameIHH Healthcare Berhad

Address

Malaysia

Representative

Dr. Tan See Leng,Managing Director and CEO

Business operation

Healthcare related business such as hospital management
and medical institution management etc. in Asia, Central andEastern Europe, the Middle East and the North Africa region
Mitsui & Co., Ltd. 18%,Others 82%

Shareholdingstructure（aftertransfer）
For inquiries on this matter, please contact:

Mitsui & Co., Ltd.
Investor Relations Division
Telephone: +81-3-3285-7910
Facsimile: +81-3-3285-9821
infoTKADZ@mitsui.com
Mitsui & Co., Ltd.
Corporate Communications Division
Telephone: +81-3-3285-6645
Facsimile: +81-3-3285-9819

Notice:This announcement contains forward-looking statements. These forward-looking
statements are based on Mitsui's current assumptions, expectations and beliefs
in light of the information currently possessed by it and involve known andunknown risks, uncertainties and other factors. Such risks, uncertainties andother factors may cause Mitsui's actual results, financial position or cash flows to
be materially different from any future results, financial position or cash flows
expressed or implied by these forward-looking statements. These risks,
uncertainties and other factors referred to above include, but are not limited to,those contained in Mitsui's latest Annual Securities Report and Quarterly
Securities Report, and Mitsui undertakes no obligation to publicly update or revise
any forward-looking statements.
This announcement is published in order to publicly announce specific facts
stated above, and does not constitute a solicitation of investments or any similar
act inside or outside of Japan, regarding the shares, bonds or other securitiesissued by us.
The information contained in this release is true and accurate at the time ofpublication; however, it may be subject to change without prior notice.